Source: International Congress 2019 – Clinical studies of asthma treatments
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Liu (Chengdu, China), J. Li (Guangzhou, China), J. Yang (Beijing, China), L. Wang (Beijing, China), M. Humphries (Beijing, China), I. Ioannis Kottakis (Bazel, Switzerland), R. Fogel (East Hanover, United States of America), X. Lau (Petaling Jaya, Malaysia), N. Zhong (Guangzhou, China). Free serum IgE suppression with omalizumab and clinical outcomes in asthma. 2545

Member's Comments

No comment yet.

Related content which might interest you: Monitoring free serum IgE in asthma patients treated with omalizumab Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Monitoring free serum IgE in severe asthma patients treated with omalizumab Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Returning asthma symptoms correlate with free IgE upon omalizumab cessation Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Correlation between specific serum IgE and exhaled NO levels at low and high inhaled corticosteroid use in allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 276s Year: 2005 Omalizumab decreases IgE production in patients with severe allergic asthma Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 Epidemiology of serum IgE in children with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 373s Year: 2001 Specific serum IgE is associated with seasonal symptom load in children with allergic rhinitis Source: Annual Congress 2008 - Risk factors for allergic asthma and allergic rhinitis Year: 2008 Long-term safety and tolerability of omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma Source: Eur Respir J 2002; 20: 1088-1094 Year: 2002 Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 47s Year: 2005 Relationship between omalizumab efficacy and baseline allergen profile impacts patient-reported outcomes in allergic asthma Source: International Congress 2018 – Tests and trends in asthma Year: 2018 Possible impact of serum IgE variability on dose calculation of omalizumab (anti-IgE) Source: Eur Respir J 2004; 24: Suppl. 48, 220s Year: 2004 Relationship between pre-treatment specific IgE and the response to omalizumab therapy Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentrations Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015 Improved disease control in asthmatics treated with daclizumab is not associated with changes in allergen-specific or total IgE Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Source: Eur Respir J 2001; 18: 254-261 Year: 2001 Treatment of asthma above and beyond anti IgE: an update for the clinician The use of biologicals in asthma treatment Source: International Congress 2018 – Difficult paediatric lung disease Year: 2018 Quantitative IgE levels in asthma and implications for treatment with omalizumab. Are the cutoffs to narrow? Source: Annual Congress 2011 - Asthma management and response Year: 2011 Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002 Correlation of changes of IgE with skin reactivity and clinical outcome during specific immunotherapy against home dust in asthmatic subjects Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma Year: 2012